John Oxler, MD
Internal Medicine · Shawnee Mission, KSNPI 1083619555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 562 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,886 and has fallen 70.0% since, to $565 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$840
- Lilly USA, LLC$821
- Pfizer$629
- Amgen$486
- AstraZeneca$454
- plus $4K from 54 others
What the payments were for
- Food & beverage$8,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,776 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $101,329 |
| XareltoRivaroxaban | 56 | $56,075 |
| JardianceEmpagliflozin | 37 | $46,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,765 |
| JanuviaSitagliptin Phosphate | 17 | $15,779 |
| FarxigaDapagliflozin Propanediol | 16 | $11,447 |
| LinzessLinaclotide | 15 | $7,428 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $4,721 |
| Atorvastatin Calcium | 602 | $3,972 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,736 |
| Gabapentin | 268 | $3,577 |
| Levothyroxine Sodium | 372 | $3,497 |
| Tamsulosin Hcl | 267 | $3,125 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,121 |
| Pantoprazole Sodium | 255 | $3,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $629 | $101,329101 claims |
| Johnson & JohnsonXarelto | $145 | $56,07556 claims |
| Boehringer IngelheimJardiance | $394 | $46,37837 claims |
| GSKTrelegy Ellipta | $169 | $20,76518 claims |
| MerckJanuvia | $124 | $15,77917 claims |
| AstraZenecaFarxiga | $454 | $11,44716 claims |
| AbbVieLinzess, Synthroid | $1,623 | $9,93653 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $3,497372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Shawnee Mission
- Charles RaglandShawnee Mission$11K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.